Lifesci Capital Has Negative Estimate for OVID Q1 Earnings

Ovid Therapeutics (NASDAQ:OVID) – Analysts at Lifesci Capital dropped their Q1 2026 earnings per share estimates for Ovid Therapeutics in a research note issued to investors on Tuesday, March 24th. Lifesci Capital analyst F. Brisebois now forecasts that the company will post earnings per share of ($0.11) for the quarter, down from their prior estimate of ($0.08). Lifesci Capital has a “Outperform” rating and a $4.00 price objective on the stock. The consensus estimate for Ovid Therapeutics’ current full-year earnings is ($0.40) per share. Lifesci Capital also issued estimates for Ovid Therapeutics’ Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.09) EPS and Q4 2026 earnings at ($0.10) EPS.

Ovid Therapeutics (NASDAQ:OVID) last issued its quarterly earnings results on Wednesday, March 18th. The company reported $0.06 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.16. The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $0.06 million. Ovid Therapeutics had a negative return on equity of 23.98% and a negative net margin of 240.11%.

A number of other research firms have also recently issued reports on OVID. Wedbush raised their price target on shares of Ovid Therapeutics from $5.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday, March 20th. Roth Mkm started coverage on shares of Ovid Therapeutics in a report on Thursday, December 11th. They set a “buy” rating and a $3.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $2.00 target price on shares of Ovid Therapeutics in a research report on Monday, December 22nd. Weiss Ratings restated a “sell (d-)” rating on shares of Ovid Therapeutics in a research note on Thursday, January 22nd. Finally, Wall Street Zen raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $4.43.

Ovid Therapeutics Stock Down 0.8%

OVID stock opened at $2.40 on Thursday. The stock has a market capitalization of $170.90 million, a PE ratio of -7.74 and a beta of 0.25. Ovid Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.72. The company has a quick ratio of 8.97, a current ratio of 8.97 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $1.75 and a 200 day moving average of $1.60.

Institutional Trading of Ovid Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its holdings in shares of Ovid Therapeutics by 49.7% in the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock valued at $53,000 after acquiring an additional 18,841 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Ovid Therapeutics by 12.8% during the first quarter. Acadian Asset Management LLC now owns 2,088,046 shares of the company’s stock worth $650,000 after purchasing an additional 237,445 shares during the last quarter. Marshall Wace LLP acquired a new position in Ovid Therapeutics during the second quarter valued at $54,000. Velan Capital Investment Management LP lifted its position in Ovid Therapeutics by 64.9% during the second quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company’s stock valued at $53,000 after purchasing an additional 63,000 shares during the period. Finally, Jane Street Group LLC purchased a new stake in Ovid Therapeutics in the second quarter valued at $47,000. 72.24% of the stock is currently owned by institutional investors and hedge funds.

Ovid Therapeutics Company Profile

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.